James Clavijo

James Clavijo brings over 25 years of experience in executive, finance, and accounting activities. He served as an Officer in the U.S. Army for 13 years in active and reserve duty. Mr. Clavijo received a bachelor's degree in Chemistry from the University of Florida, a bachelor's degree in Accounting from the University of Nebraska, and a master's degree in Accounting from Florida International University.

He has served as CFO for biotech, medical technology, and pharmaceutical companies, including Longeveron (NASDAQ: LVGN), Guided Therapeutics (OTC: GTHP), Aeterna Zentaris (NASDAQ: AEZS), and Tri-source Pharma. Prior to serving as Chief Financial Officer of Tri-Source Pharma, Mr. Clavijo also served for seven years as founder of Capital View Partners, a consulting firm providing Chief Financial Officer services, and for five years as the Chief Accounting Officer at Soligenix, a public biopharmaceutical company.

Career history

• Chief Financial Officer, Mannatech, Incorporated (July 2024–June 2026)
• Chief Financial Officer, Aeterna Zentaris (NASDAQ: AEZS) (March 2018)
• Chief Financial Officer, Tri-Source Pharma
• Chief Accounting Officer, Soligenix (5 years)
• Founder and Principal, Barcelona Capital Partners consulting firm (since 2009)

Mr. Clavijo has led and advised companies with strategic plans for pharmaceutical commercialization and manufacturing, has negotiated licensing and drug development agreements, and he has advised companies with complex restructurings, mergers, acquisitions, capital market transactions, and system implementations. What James Clavijo could bring to his role at Mannatech: His extensive track record in biotech and pharmaceutical finance—including experience with NASDAQ and OTC-listed companies, drug development agreements, and manufacturing operations—positioned him to oversee Mannatech's global finance organization and create shareholder value in the health and wellness sector.